"MIRACLE" FAT-MELTING DRUG OZEMPIC HAS been linked in a study to a series of rare but potentially fatal psychiatric episodes, scientists have warned.
The injectable prescription drug was developed to manage blood sugar levels in patients with Type 2 diabetes, but it has gained popularity and gone viral on social media due to one sought-after side effect: weight loss.
Ozempic is based on a naturally occurring human hormone called glucagon-like peptide 1, which plays an important role in regulating appetite and blood sugar levels. Its active ingredient is a molecule called semaglutide, which mimics the structure of this GLP-1 hormone and activates its receptors.
In doing so, semaglutide induces feelings of fullness while delaying the emptying of our stomach, making us less hungry and therefore less likely to overeat.
Semaglutide is also used in Ozempic's sister drug, Wegovy, which has been approved by the FDA for chronic weight management. Between the start of 2020 and the end of 2022, prescriptions of GLP-1 mimic medications like semaglutide increased by 300 percent across the U.S., according to health care analytics firm Trilliant Health.
The drug has since been endorsed by celebrities and influencers, with #ozempic reaching over 1.4 billion views on TikTok. However, when used as a weight-loss drug, semaglutide has been shown to have some uncomfortable side effects.
Most studies into these have focused on gut problems, but a new study, published in the International Journal of Clinical Pharmacy, has highlighted a concerning association between semaglutide and adverse psychiatric events, including depression, anxiety and suicidal thoughts. Pharmaceutical manufacturer Novo Nordisk, which produces Ozempic and Wegovy, cited the FDA saying that no evidence was found regarding suicidal thoughts or actions caused by these medicines.
This story is from the March 22, 2024 edition of Newsweek US.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the March 22, 2024 edition of Newsweek US.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Sign In
Mark-Paul Gosselaar
HE'S BEEN IN THE BUSINESS FOR MORE THAN 40 years, but Mark-Paul Gosselaar still feels like he hasn't experienced everything.
The SECOND COMING
As he returns to the Oval Office, DONALD TRUMP has promised 'a golden age' after he was 'saved by God to make America great again.' Is his optimism justified?
Chatbot Therapy
Could artificial intelligence replace human support for mental health care? Newsweek asked the experts
TRUMP'S LICENSE TO DRILL
After pumping money into the election cycle, the oil and gas industry now want the president to follow through on his pledge
Failed Lovers, Lifelong Friends
'What initially attracted you to a person need not be wasted...it can be used to build something new'
Animal Instincts
Primates practice different mating styles but empowered females help create harmonious families. Humans could learn from them
Morris Chestnut
FROM BOYZ N THE HOOD IN 1991 UNTIL NOW, MORRIS CHESTNUT HAS SEEN much of Hollywood.
MOST TRUSTED BRANDS 2025
TRUST IS A CORNERSTONE OF MEANINGFUL RELAtionships. When dealing with businesses and brands, it's often the deciding factor that separates the companies we rely on from the ones we don't.
Kenya Barris
KENYA BARRIS, THE EMMY-NOMINATED CRE-ator of Black-ish, knows that him teaming up with Malcolm Gladwell for the new Audible series The Unusual Suspects is a bit of an odd pairing. “We’re actually not as odd, but it’s an interesting combination.” And their guest list is just as diverse, from entertainment figures like Jimmy Kimmel and Ava DuVernay to renowned chef David Chang.
The Man Behind Israel's Charm Offensive
Gideon Sa’ar wants to change the world’s perception of his country. Some say the Israeli foreign minister will need to be a real magician’ to pull it off
